Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,136
Total Claims
$6.4M
Drug Cost
824
Beneficiaries
$7,770
Cost/Patient
Risk Score Breakdown 28/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
-58%
Opioid rate vs peers
1.6% vs 3.8% avg
+562%
Cost per patient vs peers
$7,770 vs $1,174 avg
+291%
Brand preference vs peers
34.6% vs 8.9% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 562% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
1.6%
Opioid Rate
179
Opioid Claims
$3,025
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,809 claims · $5.9M
Generic: 7,186 claims · $448K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 657 | $1.4M |
| Apixaban | 347 | $509K |
| Fluticasone/Umeclidin/Vilanter | 157 | $288K |
| Insulin Degludec | 129 | $272K |
| Rivaroxaban | 189 | $231K |
| Semaglutide | 81 | $175K |
| Empagliflozin | 100 | $174K |
| Insulin Aspart | 98 | $171K |
| Dapagliflozin Propanediol | 96 | $139K |
| Insulin Degludec | 88 | $124K |
| Apremilast | 20 | $122K |
| Sacubitril/Valsartan | 67 | $110K |
| Tirzepatide | 53 | $100K |
| Mirabegron | 79 | $97K |
| Linaclotide | 76 | $96K |
Prescribing Profile
Patient Profile
71
Avg Age
52%
Female
1.32
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About